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WOMEN'S HEALTH

Osteoporosis and ERT-The jury is still out
As most readers of JAMWA will know, the Public Health Service formed a
Task Force on Women's Health Issues in 1983. Each agency of the Public
Health Service now has a Women's Health Coordinating Committee. The
committee at the Centers for Disease Control has decided to focus on
publicizing selected women's health issues as well as providing a forum for
discussion and debate. Although the Task Force issued a two-volume report,
many of the issues covered in the report have not had the publicity we think
they deserve. We hope that airing the issues will be a catalyst to action for
·researchers and public health authorities as well as physicians dedicated to
patient care. That is why we have initiated this new column in JAMWA.
Our first topic, osteoporosis, has received much media attention, perhaps
too much, especially in women's magazines. But there are still some
questions-about the wisdom of estrogen replacement therapy, for example-that deserve closer consideration and further research. This report is
based on an NIH-sponsored workshop, "Research Directions in Osteoporosis," held February 9-11, 1987, and a critical review of the data by
Barrett-Connor.
-CDC Women's Health Coordinating Committee

Mary E. Guinan, MD, PhD; Karen Steinberg, PhD; Lambertina
Freni-Titulaer, MD, MSPH
Bone loss in women accelerates
immediately after menopause, often
leading to osteoporosis and an
increased risk of bone fractures. In
1985,247,000 hip fractures occurred
in people over 45 years of age.
Among those who live to be 90,
one-third of women and one-sixth of
men will experience hip fractures.
Six months after fracture, 25% of
victims will not be able to carry out
their usual activities, and 50% will
need assistance to do so. Hip fractures are not only a serious cause of
morbidity but they also increase the
risk of mortality in older people.
Because the proportion of the population over 65 will increase steadily,
from 11% in 1981 to 22% in 2050,
the estimated number of hip fractures will triple by the year 2050.
Established risk factors for osteoporosis include being thin, white, and
female. Alcohol consumption, cigarette smoking, and low dietary calcium may also increase risk. Estrogen
use retards postmenopausal bone loss
and reduces the risk of osteoporosis.
The risk of hip fracture is considerably reduced in women who use post-
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menopausal estrogens. For maximum effect, estrogen should be
started as soon as possible after
menopause. The suggested dose is
0.625 mg, but the optimal duration
of use is unknown. Experts suggest a
minimum of five to ten years.
Should all women be aavised to
take postmenopausal estrogens? It
has been estimated that at present
approximately 40 million women in
the United States are functionally
postmenopausal, but only about 4 to
5 million of them are taking estrogen. Other factors besides the beneficial effect on osteoporosis must be
taken into consideration before
deciding on the use of postmenopausal estrogen.
In a recent review, Barrett-Connor1 stated that postmenopausal
estrogen replacement was associated
with an established increased risk of
endometrial cancer and a possibly
increased risk of breast cancer and
an established decreased risk of both
osteoporosis and cardiovascular disease. She emphasized that almost all
risk data available were based on
estrogen therapy with conjugated

equine estrogen (Premarin*) given in
doses ranging from 0.625 mg to 1.25
mg without a progestin. It cannot be
assumed that other estrogen preparations have the same risks and benefits. Nor can it be assumed that
estrogens given with progestins will
have the same effects.
Multiple case control studies have
found an association between endometrial cancer and estrogen replacement therapy with the risk generally
increasing with dose and duration of
use. The American College of
Obstetrics and Gynecology has recommended that estrogen replacement therapy include a progestin to
reduce endometrial cancer. Although
biologically plausible, not enough
data exist to definitely state that the
addition of a progestin will mitigate
the increased risk of endometrial
cancer associated with estrogen
replacement. And even more worrisome are the possible adverse effects
of added progestins on breast cancer
and cardiovascular disease.
Exogenous estrogen use has not
been associated with breast cancer in
most studies; however, long-term follow-up is necessary to exclude risk.
The addition of progestin to estrogen
replacement has not been studied
sufficiently to determine its effect on
breast cancer, although one study
suggests that estrogen-progestin
therapy was protective against breast
cancer compared to estrogen alone or
no estrogen.2
For women over age 65 in the
United States, the death rate from
myocardial infarction increases dramatically each year, and it greatly
exceeds rates for both breast and
endometrial cancer. If postmenopausal estrogen therapy had a benefi-

*Trade names are used for identification
purposes and do not constitute endorsement by the Centers for Disease Control
or the U. S. Public Health Service.

cial effect on cardiovascular risk, a
stronger case might be made for its
use in the prevention of ischemic
heart disease than in the prevention
of osteoporosis. However, the data on
estrogen use and risk of heart disease
are conflicting. In two studies published together in 1985, one showed
an increased risk and the other
showed a decreased risk of coronary
artery disease associated with exogenous estrogen use. 3•4 The weight of
the evidence at present, however,
suggests that postmenopausal estrogen use decreases the risk of cardiovascular disease. Barrett-Connor 1
points out that a progestin supplement may reverse the potential cardiovascular benefit of estrogen use
by blocking the estrogen-induced
increase in high density lipoprotein
cholesterol.
One side effect of estrogen
replacement therapy is vaginal bleeding. This may lead to an increase in
diagnostic dilation and curettage
procedures and to an increased rate
of hysterectomy. If progestins are
added, menstrual periods will likely
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ensue. Many women may refuse
estrogen-progestin replacement therapy because they do not want to
continue menstruating after menopause. In fact, very little information
is available on how women decide
whether or not to take estrogen
replacement at the time of menopause. Another side effect of estrogen replacement therapy is an
increase in gall bladder disease.
One interesting new area is the use
of transdermal estradiol. Preliminary
evidence suggests that estrogen taken
by nonoral routes may be effective
against osteoporosis and have fewer
side effects than oral estrogens.
However, transdermal patch estradiol has not yet been studied in wellcontrolled trials.
As this summary suggests, many
questions exist concerning the use of
postmenopausal estrogens. The decision to prescribe estrogen must be
made after considering the risks and
benefits to the individual patient.
Women receiving estrogen should be
examined frequently for complica-

tions, especially vaginal bleeding.
Frequent breast examinations and
annual mammography are also
advised.
Dr. Guinan is Acting Assistant Director
for Science at the CDC. Dr. Steinberg is
a research microbiologist and Dr. FreniTitulaer a medical epidemiologist, both
of whom are studying osteoporosis.
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